Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives

被引：66

作者：

Borella, Fulvio ^{[1
]}

Ghisoni, Eleonora ^{[2
,3
]}

Giannone, Gaia ^{[2
,3
]}

Cosma, Stefano ^{[1
]}

Benedetto, Chiara ^{[1
]}

Valabrega, Giorgio ^{[2
,3
]}

Katsaros, Dionyssios ^{[1
]}

机构：

[1] Univ Turin, Dept Surg Sci, Gynecol & Obstet 1, I-10126 Turin, Italy

[2] Univ Torino, Dept Oncol, I-10060 Turin, Italy

[3] FPO IRCCS, Candiolo Canc Inst, I-10060 Candiolo, Italy

来源：

DIAGNOSTICS | 2020年 / 10卷 / 03期

关键词：

Ovarian cancer; immunotherapy; immune checkpoint inhibitors; safety; biomarkers; clinical trials; TUMOR-INFILTRATING LYMPHOCYTES; OLAPARIB MAINTENANCE THERAPY; PROGNOSTIC-SIGNIFICANCE; ANTI-PD-1; ANTIBODY; ANTITUMOR-ACTIVITY; CLINICAL ACTIVITY; SOLID TUMORS; PHASE-II; T-CELLS; SAFETY;

D O I：

10.3390/diagnostics10030146

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological cancers. Despite improvements in medical treatments, the prognosis for EOC remains poor, and there is an urgent need for new therapeutic strategies. Immune checkpoint inhibitors (CPIs) have dramatically improved survival of several cancers and are under evaluation in OC. Unfortunately, CPIs have shown globally unsatisfactory results. The aim of this manuscript is to critically review the results from early-phase trials with CPIs in terms of safety and activity, discuss the possible reasons for disappointing results and the new therapeutic approaches to improve patient outcomes.

引用

页数：17

共 76 条

[1] Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview [J].

Alme, Angela K. B. ;

Karin, Beerinder S. ;

Faltas, Bishoy M. ;

Drake, Charles G. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2016, 34 (04) :171-181

[2]

American College Health Association, 2020, CONS REOP I HIGH ED, P20

[3]

[Anonymous], P 17 BIENN M INT GYN

[4] First-line PARP inhibition in ovarian cancer - standard of care for all? [J].

Banerjee, Susana N. ;

Lord, Christopher J. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (03) :136-137

[5] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[6] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[7] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[8] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition [J].

Buchbinder, Elizabeth I. ;

Desai, Anupam .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01) :98-106

[9] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[10] Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC [J].

Champiat, Stephane ;

Ileana, Ecaterina ;

Giaccone, Giuseppe ;

Besse, Benjamin ;

Mountzios, Giannis ;

Eggermont, Alexander ;

Soria, Jean-Charles .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (02) :144-153

← 1 2 3 4 5 6 7 8 →